Humacyte, Inc. HUMA 深 沪
等待开盘 05-16 09:30:00 美东时间
0.925
-0.075
-7.50%
华盛通- 最 高1.05
- 今 开1.05
- 成交量 639.41万股
- 最 低 0.8903
- 昨 收 1.00
- 总市值 2.05亿
- 52周最高 2.93
- 市盈率 静 --
- 换手率 2.88%
- 52周最低 0.5469
- 委 比 -24.91%
- 总股本 2.22亿
- 历史最高 17.45
- 量 比 0.75
- 振 幅 15.97%
- 历史最低 0.5469
- 每 手 1
- 风险率 0.59%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 阿里、京东、英伟达、思科等获多家大行上调目标价；Doximity、Dynatrace、Enovix、Wix.com等遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Autolus Therapeutics"买入"评级，目标价从9美元升至10美元；Maxim Group：维持Rezolute"买入"评级，目标价从4美元升至10美元
05-15 10:49
美股大行评级 | 潜在涨幅257.14%！瑞杰金融上调InflaRx目标价至9美元，评级升至"强烈买入"
今日重点评级关注：瑞杰金融：上调InflaRx评级至"强烈买入"，目标价从7美元升至9美元；巴克莱：维持Orchestra BioMed Hldgs"超配"评级，目标价从12美元升至13美元
05-14 14:32
BTIG Maintains Buy on Humacyte, Lowers Price Target to $2
BTIG analyst Ryan Zimmerman maintains Humacyte (NASDAQ:HUMA) with a Buy and lowers the price target from $3 to $2.
05-14 02:09
Humacyte shares are trading higher after the company reported better-than-expected Q1 EPS results.
Humacyte shares are trading higher after the company reported better-than-expec...
05-13 23:08
Humacyte Reports Q1 2026 Results: Full Earnings Call Transcript
Humacyte (NASDAQ:HUMA) released first-quarter financial results and hosted an e...
05-13 21:29
Earnings Scheduled For May 13, 2026
Companies Reporting Before The Bell • Similarweb (NYSE:SMWB) is estimated to re...
05-13 19:11
Humacyte Q1 EPS $(0.09) Beats $(0.11) Estimate, Sales $495.000K Miss $1.455M Estimate
Humacyte (NASDAQ:HUMA) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.11) by 18.18 percent. This is a 10 percent increase over losses of $(0.10) per share from the same
05-13 19:01
美股大行评级 | 达美乐比萨惨遭10家大行下调目标价；铿腾电子、艾克尔科技、Relay 、辛普森配件制造、TFI International等获多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Intellia Therapeutics"买入"评级，目标价从48美元升至58美元；富国银行：维持曼恩凯德生物医疗"超配"评级，目标价从7美元升至8美元
04-29 10:28
BTIG Reiterates Buy on Humacyte, Maintains $3 Price Target
BTIG analyst Ryan Zimmerman reiterates Humacyte (NASDAQ:HUMA) with a Buy and maintains $3 price target.
04-28 23:42
Humacyte Realigns Ex-U.S. Rights To Symvess By Amending Its Distribution Deal With Fresenius Medical Care
Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has realigned the ex-U.S.
04-24 20:07
